Starpharma, Merck collaborate on new ADCs

By The Science Advisory Board staff writers

Starpharma has signed a research agreement with Merck to conduct preclinical research on dendrimer-based antibody-drug conjugates (ADCs) utilizing Starpharma's proprietary DEP dendrimer drug delivery technology.

DEP ADCs exploit the potential of Starpharma's DEP technology to provide enhanced characteristics including greater homogeneity, site specific attachment, and higher antibody ratio, compared to conventional ADC approaches, according to the firm.

In previous preclinical studies, DEP ADCs have shown significant tumor regression and outperformed other approved drugs in human ovarian cancer models. Financial details of the agreement were not disclosed.


Copyright © 2021 scienceboard.net
 

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a Scienceboard.net password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: